von Martin Baunacke ; Maria-Luisa Schmidt ; Christer Groeben ; Angelika Sabina Maria Borkowetz ; Christian Thomas ; Rainer Koch ; Falk Hoffmann ; Felix Chun ; Lothar Weißbach ; Johannes Huber
Journal of autism and developmental disorders Dordrecht [u.a.] : Springer Science + Business Media B.V., 1971 52(2021), 3 vom: 17. Apr., Seite 1066-1076 Online-Ressource
von Falk Hoffmann ; Thomas Kaiser ; Christian Apfelbacher ; Stefan Rolf Benz ; Thomas Bierbaum ; Karsten Dreinhöfer ; Michael Hauptmann ; Claus-Dieter Heidecke ; Michael Koller ; Tanja Kostuj ; Olaf Ortmann ; Jochen Maximilian Schmitt ; Holger J. Schünemann ; Christof Veit ; Wolfgang Hoffmann ; Monika Klinkhammer-Schalke
von Timo Stöver ; Stefan Dazert ; Stefan K.-R. Plontke ; Sabine Maria Kramer ; Petra Ambrosch ; Christoph Arens ; Christian Stephan Betz ; Dirk Beutner ; Christopher Bohr ; Karl-Ludwig Bruchhage ; Martin Canis ; Andreas Dietz ; Orlando Guntinas-Lichius ; Rudolf Hagen ; Werner Hosemann ; Heinrich Iro ; Jens Peter Klußmann ; Andreas Knopf ; Stephan Lang ; Martin Leinung ; Thomas Lenarz ; Hubert Martin Löwenheim ; Christoph Matthias ; Robert Arndt Mlynski ; Heidi Olze ; Jonas Jae-Hyun Park ; Peter K. Plinkert ; Andreas Daniel Radeloff ; Nicole Rotter ; Claudia Rudack ; Alessandro Bozzato ; Jörg H. Schipper ; Martin Schrader ; Patrick Schuler ; Sebastian Strieth ; Boris Stuck ; Stefan Volkenstein ; Martin Westhofen ; Gregor Wolf ; Barbara Wollenberg ; Thomas Zahnert ; Johannes Zenk ; Thomas K. Hoffmann
von Monika Klinkhammer-Schalke ; Thomas Kaiser ; Christian Apfelbacher ; Stefan Benz ; Karsten Dreinhöfer ; Max Geraedts ; Michael Hauptmann ; Falk Hoffmann ; Wolfgang Hoffmann ; Michael Koller ; Tanja Kostuj ; Christoph Kowalski ; Katrin Mugele ; Olaf Ortmann ; Jochen Maximilian Schmitt ; Holger J. Schünemann ; Christof Veit ; Simone Wesselmann ; Thomas Bierbaum
von Bernhard Wörmann ; Carsten Bokemeyer ; Thomas Burmeister ; Claus-Henning Köhne ; Matthias Schwab ; Dirk Arnold ; Jens-Uwe Blohmer ; Markus Borner ; Sara Brucker ; Ingolf Cascorbi ; Thomas Decker ; Maike de Wit ; Andreas Dietz ; Hermann Einsele ; Wolfgang Eisterer ; Gunnar Folprecht ; Wolfgang Hilbe ; Jürgen Hoffmann ; Wolfgang Knauf ; Volker Kunzmann ; Carlo R. Largiadèr ; Sylvie Lorenzen ; Diana Lüftner ; Markus Moehler ; Markus M. Nöthen ; Christian Pox ; Anke Reinacher-Schick ; Anton Scharl ; Brigitte Schlegelberger ; Thomas Seufferlein ; Marianne Sinn ; Matthias Stroth ; Ingo Tamm ; Lorenz Trümper ; Martin Wilhelm ; Ewald Wöll ; Ralf-Dieter Hofheinz
<b><i>Background:</i></b> 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2-1.0%. <b><i>Summary:</i></b> Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. This is due to variants in the DPD gene (<i>DPYD</i>). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and DPD is completely lacking in approximately 0.5% of patients. Here we describe the clinical and genetic background and summarize recommendations for the genetic testing and tailoring of treatment with 5-FU derivatives. The statement was developed as a consensus statement organized by the German Society for Hematology and Medical Oncology in cooperation with 13 medical associations from Austria, Germany, and Switzerland. <b><i>Key Messages:</i></b> (i) Patients should be tested for the 4 most common genetic <i>DPYD</i> variants before treatment with drugs containing FU. (ii) Testing forms the basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii) Testing may optionally be supplemented by therapeutic drug monitoring.
Oncology research and treatment Basel : Karger, 2014 43(2020), 11, Seite 628-636 Online-Ressource
Seite 3 von 7
